Published in Radiother Oncol on June 26, 2010
DNA double-strand break repair as determinant of cellular radiosensitivity to killing and target in radiation therapy. Front Oncol (2013) 1.30
Nedaplatin: a cisplatin derivative in cancer chemotherapy. Cancer Manag Res (2013) 0.90
A nucleoside anticancer drug, 1-(3-C-ethynyl-β-D-ribo-pentofuranosyl)cytosine (TAS106), sensitizes cells to radiation by suppressing BRCA2 expression. Mol Cancer (2011) 0.82
A phase I dose escalation study of S-1 with concurrent radiotherapy in elderly patients with esophageal cancer. J Thorac Dis (2016) 0.80
Clinical development of S-1 for non-small cell lung cancer: a Japanese perspective. Ther Adv Med Oncol (2013) 0.75
Phase I study of oral S-1 and concurrent radiotherapy in patients with head and neck cancer. J Radiat Res (2013) 0.75
Mutations in the FHA-domain of ectopically expressed NBS1 lead to radiosensitization and to no increase in somatic mutation rates via a partial suppression of homologous recombination. J Radiat Res (2014) 0.75
Therapeutic strategies with oral fluoropyrimidine anticancer agent, S-1 against oral cancer. Jpn Dent Sci Rev (2016) 0.75
Gimeracil enhances the antitumor effect of cisplatin in oral squamous cell carcinoma cells in vitro and in vivo. Oncol Lett (2017) 0.75
Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer (2004) 4.54
Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients. Int J Radiat Oncol Biol Phys (2006) 4.26
Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol (2007) 3.91
Stereotactic body radiotherapy (SBRT) for operable stage I non-small-cell lung cancer: can SBRT be comparable to surgery? Int J Radiat Oncol Biol Phys (2010) 3.66
Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol (2014) 3.21
Cancer classification using the Immunoscore: a worldwide task force. J Transl Med (2012) 2.88
NBS1 localizes to gamma-H2AX foci through interaction with the FHA/BRCT domain. Curr Biol (2002) 2.44
Regulation of homologous recombination by RNF20-dependent H2B ubiquitination. Mol Cell (2011) 2.00
Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma. Clin Cancer Res (2006) 1.64
Peripheral vascular malformations: imaging, treatment approaches, and therapeutic issues. Radiographics (2005) 1.56
SOX2 is overexpressed in stem-like cells of human lung adenocarcinoma and augments the tumorigenicity. Lab Invest (2011) 1.52
Monoallelic BUB1B mutations and defective mitotic-spindle checkpoint in seven families with premature chromatid separation (PCS) syndrome. Am J Med Genet A (2006) 1.48
An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin. Clin Cancer Res (2002) 1.45
Up-regulation of DNA-dependent protein kinase activity and Sp1 in colorectal cancer. Int J Oncol (2004) 1.42
NBS1 and its functional role in the DNA damage response. DNA Repair (Amst) (2004) 1.30
Homologous recombination but not nucleotide excision repair plays a pivotal role in tolerance of DNA-protein cross-links in mammalian cells. J Biol Chem (2009) 1.29
A prospective, randomized trial comparing neoadjuvant chemotherapy with radiotherapy alone in patients with advanced nasopharyngeal carcinoma. Cancer (2002) 1.26
Thoracic involvement of type A aortic dissection and intramural hematoma: diagnostic accuracy--comparison of emergency helical CT and surgical findings. Radiology (2003) 1.26
CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection. Cancer Immunol Immunother (2010) 1.25
Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors. Invest New Drugs (2008) 1.23
Differential activation of cell death and autophagy results in an increased cytotoxic potential for trifluorothymidine compared to 5-fluorouracil in colon cancer cells. Int J Cancer (2010) 1.22
Synergistic effects of docetaxel and S-1 by modulating the expression of metabolic enzymes of 5-fluorouracil in human gastric cancer cell lines. Int J Cancer (2006) 1.21
Erythropoietin affords additional cardioprotection to preconditioned hearts by enhanced phosphorylation of glycogen synthase kinase-3 beta. Am J Physiol Heart Circ Physiol (2006) 1.19
Cytotoxic T lymphocytes efficiently recognize human colon cancer stem-like cells. Am J Pathol (2011) 1.18
Efficient cross-presentation by heat shock protein 90-peptide complex-loaded dendritic cells via an endosomal pathway. J Immunol (2007) 1.18
Down-regulation of HLA class I antigen is an independent prognostic factor for clear cell renal cell carcinoma. J Urol (2007) 1.17
Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer. J Transl Med (2004) 1.17
Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors. Cancer (2006) 1.16
HLA class I antigen expression is associated with a favorable prognosis in early stage non-small cell lung cancer. Cancer Sci (2007) 1.16
Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors. Cancer Invest (2008) 1.15
Detection and induction of CTLs specific for SYT-SSX-derived peptides in HLA-A24(+) patients with synovial sarcoma. J Immunol (2002) 1.14
A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells. Int J Mol Med (2004) 1.14
A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA. Int J Oncol (2004) 1.11
High-dose-rate versus low-dose-rate intracavitary therapy for carcinoma of the uterine cervix: a randomized trial. Cancer (2002) 1.11
Cep55/c10orf3, a tumor antigen derived from a centrosome residing protein in breast carcinoma. J Immunother (2009) 1.10
Scythe/BAT3 regulates apoptotic cell death induced by papillomavirus binding factor in human osteosarcoma. Cancer Sci (2008) 1.10
A potent immunogenic general cancer vaccine that targets survivin, an inhibitor of apoptosis proteins. Clin Cancer Res (2005) 1.10
Prognostic significance of HLA class I expression in osteosarcoma defined by anti-pan HLA class I monoclonal antibody, EMR8-5. Cancer Sci (2006) 1.10
Ovarian cancer stem cells are enriched in side population and aldehyde dehydrogenase bright overlapping population. PLoS One (2013) 1.09
HSP DNAJB8 controls tumor-initiating ability in renal cancer stem-like cells. Cancer Res (2012) 1.09
The expression pattern of Ku correlates with tumor radiosensitivity and disease free survival in patients with rectal carcinoma. Cancer (2002) 1.09
Immune response against tumor antigens expressed on human cancer stem-like cells/tumor-initiating cells. Immunotherapy (2010) 1.07
Role of miR-19b and its target mRNAs in 5-fluorouracil resistance in colon cancer cells. J Gastroenterol (2012) 1.07
Repair activity of base and nucleotide excision repair enzymes for guanine lesions induced by nitrosative stress. Nucleic Acids Res (2005) 1.06
Phase I vaccination trial of SYT-SSX junction peptide in patients with disseminated synovial sarcoma. J Transl Med (2005) 1.06
Three cases of diffuse large B-cell lymphoma of the mandible treated with radiotherapy and chemotherapy. Radiat Med (2005) 1.06
The association of DNA-dependent protein kinase activity with chromosomal instability and risk of cancer. Carcinogenesis (2005) 1.05
Prognostic impact and immunogenicity of a novel osteosarcoma antigen, papillomavirus binding factor, in patients with osteosarcoma. Cancer Sci (2008) 1.04
Molecular pathological approaches to human tumor immunology. Pathol Int (2009) 1.04
TopBP1 associates with NBS1 and is involved in homologous recombination repair. Biochem Biophys Res Commun (2007) 1.03
ALDH1-high ovarian cancer stem-like cells can be isolated from serous and clear cell adenocarcinoma cells, and ALDH1 high expression is associated with poor prognosis. PLoS One (2013) 1.03
Immunotherapeutic benefit of α-interferon (IFNα) in survivin2B-derived peptide vaccination for advanced pancreatic cancer patients. Cancer Sci (2012) 1.02
Multi-institutional analysis of early squamous cell carcinoma of the hypopharynx treated with radical radiotherapy. Int J Radiat Oncol Biol Phys (2006) 1.02
The functioning antigens: beyond just as the immunological targets. Cancer Sci (2009) 1.01
Phase I clinical study of anti-apoptosis protein survivin-derived peptide vaccination for patients with advanced or recurrent urothelial cancer. Cancer Immunol Immunother (2009) 1.00
Potentiation of the antitumor activity of alpha, alpha, alpha-trifluorothymidine by the co-administration of an inhibitor of thymidine phosphorylase at a suitable molar ratio in vivo. Int J Oncol (2005) 1.00
Thymidylate synthase, dihydropyrimidine dehydrogenase, orotate phosphoribosyltransferase mRNA and protein expression levels in solid tumors in large scale population analysis. Int J Mol Med (2008) 1.00
IL12RB2 and ABCA1 genes are associated with susceptibility to radiation dermatitis. Clin Cancer Res (2008) 0.99
Identification of human autologous cytotoxic T-lymphocyte-defined osteosarcoma gene that encodes a transcriptional regulator, papillomavirus binding factor. Cancer Res (2004) 0.99
Current topics in DNA double-strand break repair. J Radiat Res (2008) 0.99
Immunogenic enhancement and clinical effect by type-I interferon of anti-apoptotic protein, survivin-derived peptide vaccine, in advanced colorectal cancer patients. Cancer Sci (2011) 0.99
The feasibility of Cep55/c10orf3 derived peptide vaccine therapy for colorectal carcinoma. Exp Mol Pathol (2010) 0.99
Heat shock protein DNAJB8 is a novel target for immunotherapy of colon cancer-initiating cells. Cancer Sci (2014) 0.99
Therapeutic potential of the dual-targeted TAS-102 formulation in the treatment of gastrointestinal malignancies. Cancer Sci (2007) 0.99
S-1, an oral fluoropyrimidine, enhances radiation response of DLD-1/FU human colon cancer xenografts resistant to 5-FU. Oncol Rep (2006) 0.99
Aberrant methylation of DPYD promoter, DPYD expression, and cellular sensitivity to 5-fluorouracil in cancer cells. Clin Cancer Res (2004) 0.99
Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer. J Transl Med (2008) 0.98
NBS1 recruits RAD18 via a RAD6-like domain and regulates Pol η-dependent translesion DNA synthesis. Mol Cell (2011) 0.98
Expression of thymidylate synthase is correlated with proliferative activity in non-small cell lung cancer (NSCLC). Lung Cancer (2004) 0.98
Extracellular heat shock protein 90 plays a role in translocating chaperoned antigen from endosome to proteasome for generating antigenic peptide to be cross-presented by dendritic cells. Int Immunol (2011) 0.98
A multi-institutional retrospective analysis of external radiotherapy for mucosal melanoma of the head and neck in Northern Japan. Int J Radiat Oncol Biol Phys (2004) 0.98
Localization of intestinal bleeding using a fusion of Tc-99m-labeled RBC SPECT and X-ray CT. Clin Nucl Med (2005) 0.98
Does contrast-enhanced ultrasound reveal tumor angiogenesis in pancreatic ductal carcinoma? A prospective study. Ultrasound Med Biol (2008) 0.97
Gene expression in colorectal cancer and in vitro chemosensitivity to 5-fluorouracil: a study of 88 surgical specimens. Cancer Sci (2003) 0.97
Sensitivity of human cancer cells to the new anticancer ribo-nucleoside TAS-106 is correlated with expression of uridine-cytidine kinase 2. Jpn J Cancer Res (2002) 0.97
Anti-angiogenic effect of 5-Fluorouracil-based drugs against human colon cancer xenografts. Cancer Lett (2008) 0.96
Activation of antioxidative enzymes induced by low-dose-rate whole-body gamma irradiation: adaptive response in terms of initial DNA damage. Radiat Res (2006) 0.96
Dancing on damaged chromatin: functions of ATM and the RAD50/MRE11/NBS1 complex in cellular responses to DNA damage. J Radiat Res (2008) 0.96
Heat-shock proteins as endogenous ligands building a bridge between innate and adaptive immunity. Immunotherapy (2012) 0.96
Ability to repair DNA double-strand breaks related to cancer susceptibility and radiosensitivity. Radiat Med (2007) 0.96
Mode of action of trifluorothymidine (TFT) against DNA replication and repair enzymes. Int J Oncol (2011) 0.96
Novel spliced form of a lens protein as a novel lung cancer antigen, Lengsin splicing variant 4. Cancer Sci (2009) 0.95
Trifluorothymidine resistance is associated with decreased thymidine kinase and equilibrative nucleoside transporter expression or increased secretory phospholipase A2. Mol Cancer Ther (2010) 0.95